Prostate Carcinoma: this chapter outlines the incidence, risk factors, clinical presentation, investigations, treatments and prognosis of cancer at this anatomical site. These features are correlated with the core data that are required to make corresponding histopathology reports of a consistently high ...
Outlines were traced sequentially onto a sheet of paper. Study of the paper "map" identified the largest cancer, which was almost always the clinically detected cancer as well as the most poorly differentiated cancer.2 The largest cancer alone was selected for further study and its volume was ...
Magnetic Resonance Imaging (MRI) is increasingly being used to detect prostate cancer, yet its interpretation can be challenging due to subtle differences between benign and cancerous tissue. Recently, Denoising Diffusion Probabilistic Models (DDPMs) have shown great utility for medical image segmentation...
1. FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix. Published online December 20, 2021. Accessed December 20, 2021. https://bit.ly/3J8Wgan 2. FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. Press release. FDA. December 1, 2020. Accessed Dece...
Androgen deprivation therapy (ADT) targeting androgen/androgen receptor (AR)- signaling pathways is the main therapy for advanced prostate cancer (PCa). However, ADT eventually fails in most patients who consequently develop castration-resistant prostate
Metastatic prostate cancer is a highly heterogeneous and dynamic disease and practicable tools for patient stratification and resistance monitoring are urgently needed. Liquid biopsy analysis of circulating tumor cells (CTCs) and circulating tumor DNA are promising, however, comprehensive testing is essential...
production. GEMs have been used to develop new strategies to selectively target cancer metabolism16,17, including in prostate cancer18. However, current cancer GEMs are mostly based on bulk transcriptomics data that do not capture the spatial or cellular heterogeneity of the tumor microenvironment (...
Deep Bio, a local diagnostic company, said its prostate cancer analysis algorithm, DeepDx Prostate, will be integrated into Roche Diagnostics' Navify Digital Pathology platform.Through this collaboration, Deep Bio aims to enhance its digital pathology ca
Objective. To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men. Methods. An in-patient c...
cancerous tissue as part of the prostate, which is wrong since this tissue is still prostate even though that the tissue characteristics are different, yet it should still be segmented as prostate. The Dense-2 U-net was able to segment this cancerous tissue as part of the prostate, some ...